Not everyone in the little people community is advocating for the controversial drug that’s promising to increase the growth of people with achondroplasia, the most common type of dwarfism.
is a rare genetic bone growth disorder that stunts growth, causing dwarfism. People with the condition experience stunted bone growth in the arms and legs, spine, and base of skull, on average reaching 4 feet, 4 inches for men, and 4 feet, 1 inch for women. The condition causes patients to have an issue with their cartilage’s ability to convert to bone. The term “achondroplasia” means “without cartilage formation.” It also can cause patients to have other physical curvatures, including spinal cord curvature and compression, bowed legs, decreased muscle tone, apnea, and difficulty bending elbows.
In 2011, the community finally found answers when scientists discovered the small molecule CNP, a key regulator of bone growth. This led to the manifestation of the novel drug, which could potentially stimulate bone growth in children. Ravi began trials in 2013, and they found success in increasing growth and confirmed that the drug was largely well tolerated. He explains the effect as similar to overwatering a plant:
As explained in News AU
, Daisy Broadway made the choice to go ahead with the treatment for her son Casper, noting that while it promises him the same height expectations as his peers, it also helps him avoid potential surgeries and complications down the road. Still, she’s careful with divulging their health care choice to too many people. Broadway said,